Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system

被引：14

作者：

Zhang, Huan ^{[1
]}

Liu, Man ^{[2
]}

Li, Qing ^{[1
]}

Lyu, Cuicui ^{[1
]}

Jiang, Yan-Yu ^{[1
]}

Meng, Juan-Xia ^{[1
]}

Li, Jing-Yi ^{[1
]}

Deng, Qi ^{[1
]}

机构：

[1] Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Hematol, Tianjin, Peoples R China

[2] Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Surg Plast, Tianjin, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 02期

关键词：

Humanized anti-CD19 CART; older patients; R; R DLBCL; comprehensive geriatric assessment; safety evaluation; CAR-T; MANAGEMENT; TISAGENLECLEUCEL; DIAGNOSIS;

D O I：

10.1080/10428194.2021.1986216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has led to unprecedented results to date in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), yet its clinical application in elderly patients with R/R DLBCL remains somewhat limited. In this study, a total of 31 R/R DLBCL patients older than 65 years of age were enrolled and received humanized anti-CD19 CAR T-cell therapy. Patients were stratified into a fit, unfit, or frail group according to the comprehensive geriatric assessment (CGA). The fit group had a higher objective response (OR) rate (ORR) and complete response (CR) rate than that of the unfit/frail group, but there was no difference in the part response (PR) rate between the groups. The unfit/frail group was more likely to experience AEs than the fit group. The peak proportion of anti-CD19 CAR T-cells in the fit group was significantly higher than that of the unfit/frail group. The CGA can be used to effectively predict the treatment response, adverse events, and long-term survival.

引用

页码：353 / 361

页数：9

共 50 条

[21] Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma [J].

Jiang, Yi Li ;

Mu, Juan ;

Cui, Rui ;

Li, Xin ;

Wang, Jia ;

Li, Qing ;

Li, Jingyi ;

Mou, Nan ;

Deng, Qi .

CANCER MEDICINE, 2024, 13 (04)

[22] Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia [J].

Heng, Gang ;

Jia, Jiankun ;

Li, Shiqi ;

Fu, Gang ;

Wang, Meiling ;

Qin, Dabing ;

Li, Yunyan ;

Pei, Li ;

Tian, Xiaobo ;

Zhang, Jiasi ;

Wu, Yi ;

Xiang, Shali ;

Wan, Jia ;

Zhu, Wei ;

Zhang, Pei ;

Zhang, Qianzhen ;

Peng, Xi ;

Wang, Linling ;

Wang, Ping ;

Wei, Zhihao ;

Zhang, Yingzi ;

Wang, Guiqin ;

Chen, Xue ;

Zhang, Chengcheng ;

Sun, Yanni ;

Zhao, Wenxu ;

Fan, Yahan ;

Yang, Zhi ;

Chen, Jieping ;

Qian, Cheng .

CLINICAL CANCER RESEARCH, 2020, 26 (07) :1606-1615

[23] Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma [J].

Xue, Fei ;

Liu, Rui ;

Fu, Zhonghua ;

Zheng, Peihao ;

Yang, Fan ;

Feng, Shaomei ;

Guo, Yuelu ;

Shi, Hui ;

Ma, Lixia ;

Deng, Biping ;

Ke, Xiaoyan ;

Hu, Kai .

CYTOTHERAPY, 2025, 27 (08) :910-916

[24] Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma [J].

Mulholland, Nicola ;

Chandra, Julie ;

Sanderson, Robin ;

Kuhnl, Andrea .

RADIOLOGY, 2023, 307 (05)

[25] Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma [J].

Bao, Fang ;

Wan, Wei ;

He, Ting ;

Qi, Feifei ;

Liu, Guanghua ;

Hu, Kai ;

Lu, Xin-an ;

Yang, Ping ;

Dong, Fei ;

Wang, Jing ;

Jing, Hongmei .

CANCER GENE THERAPY, 2019, 26 (7-8) :248-255

[26] Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach [J].

Saifi, Omran ;

Lester, Scott ;

Breen, William ;

Rule, William ;

Lin, Yi ;

Bennani, N. Nora ;

Rosenthal, Allison ;

Munoz, Javier ;

Murthy, Hemant ;

Kharfan-Dabaja, Mohamed ;

Peterson, Jennifer ;

Hoppe, Bradford .

AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (01) :124-134

[27] Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report [J].

Huang, Chen ;

Zhang, Hui-Chao ;

Ho, Jin-Yuan ;

Liu, Rui-Xia ;

Wang, Lin ;

Kuang, Na ;

Zheng, Mei-Rong ;

Liu, Li-Hong ;

Li, Jian-Qiang .

ONCOLOGY LETTERS, 2020, 20 (04)

[28] Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma [J].

Strati, Paolo ;

Ahmed, Sairah ;

Furqan, Fateeha ;

Fayad, Luis E. ;

Lee, Hun J. ;

Iyer, Swaminathan P. ;

Nair, Ranjit ;

Nastoupil, Loretta J. ;

Parmar, Simrit ;

Rodriguez, Maria A. ;

Samaniego, Felipe ;

Steiner, Raphael E. ;

Wang, Michael ;

Pinnix, Chelsea C. ;

Horowitz, Sandra B. ;

Feng, Lei ;

Sun, Ryan ;

Claussen, Catherine M. ;

Hawkins, Misha C. ;

Johnson, Nicole A. ;

Singh, Prachee ;

Mistry, Haleigh ;

Johncy, Swapna ;

Adkins, Sherry ;

Kebriaei, Partow ;

Shpall, Elizabeth J. ;

Green, Michael R. ;

Flowers, Christopher R. ;

Westin, Jason ;

Neelapu, Sattva S. .

BLOOD, 2021, 137 (23) :3272-3276

[29] Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma [J].

Cordeiro, Ana Costa ;

Durisek, George ;

Batista, Marjorie Vieira ;

Schmidt, Jayr ;

de Lima, Marcos ;

Bezerra, Evandro .

FRONTIERS IN ONCOLOGY, 2024, 14

[30] Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma [J].

Sharp, John ;

Zhao, Qiuhong ;

Voorhees, Timothy J. ;

Bond, David A. ;

Sawalha, Yazeed ;

Reneau, John ;

Sigmund, Audrey ;

Hanel, Walter ;

Sehgal, Lalit ;

Alinari, Lapo ;

Baiocchi, Robert ;

Brammer, Jonathan E. ;

Maddocks, Kami ;

Christian, Beth ;

Bezerra, Evandro ;

Denlinger, Nathan ;

Vasu, Sumithira ;

De Lima, Marcos ;

Prosek, Jason ;

Epperla, Narendranath .

BRITISH JOURNAL OF HAEMATOLOGY, 2025,

← 1 2 3 4 5 →